相关临床试验
6
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2014
已完成
3
50.0%
招募中
2
33.3%
Unknown
1
16.7%
暂无批准数据
- Emergent BioSolutions announced a multi-year, $50 million manufacturing agreement with SAB Biotherapeutics to support development and production of SAB-142, a novel therapy for autoimmune type 1 diabetes. - SAB-142 represents a disease-modifying therapeutic approach that aims to delay onset and potentially prevent progression of Stage 3 type 1 diabetes, currently being evaluated in a registrational Phase 2b trial. - The agreement leverages Emergent's Winnipeg facility for end-to-end manufacturing services, with $36 million contingent on regulatory approval and commercial milestones. - SAB Biotherapeutics utilizes proprietary transchromosomic cattle technology to produce human immunoglobulin G antibodies without requiring human donors or convalescent plasma.
- The global influenza pipeline has expanded to include 120+ companies developing 120+ treatment therapies, with breakthrough innovations spanning vaccines, antibodies, and combination therapies. - Moderna's mRNA-1083 combination vaccine achieved primary endpoints in Phase III trials, demonstrating stronger immune responses than licensed comparator vaccines for both influenza and COVID-19. - AstraZeneca launched FluMist Home in August 2025, marking the first FDA-approved influenza vaccine for self-administration or caregiver delivery at home. - Leading pipeline candidates include Moderna's mRNA-1010 seasonal vaccine, SAB Biotherapeutics' broadly neutralizing antibody SAB-176, and innovative intranasal therapies targeting multiple respiratory viruses.
- SAB Biotherapeutics' SAB-142 completes Phase 1 enrollment in healthy volunteers, advancing to enroll patients with type 1 diabetes (T1D). - The Phase 1 trial of SAB-142 demonstrates no serum sickness at the target dose of 2.5mg/kg, a key differentiator from rabbit anti-thymocyte globulin. - SAB-142, a human anti-thymocyte immunoglobulin, aims to delay the onset and progression of T1D by preserving insulin-producing beta cells. - Topline Phase 1 data readout for SAB-142 is expected by the end of the year, with plans for a Phase 2 SAFEGUARD study in new-onset T1D patients.
